Patent classifications
G01N33/92
CONCENTRATION DEVICE, SAMPLE SOLUTION CONCENTRATION METHOD, SAMPLE SOLUTION EXAMINATION METHOD, AND EXAMINATION KIT
There are provided a concentration device for concentrating a sample solution, which makes it possible to obtain a sample solution concentrated solution having a desired concentration fold ratio, a sample solution concentration method using the concentration device, a sample solution concentration method using the sample solution examination method, and an examination kit including the concentration device. The concentration device is a concentration device for concentrating a sample solution which is an aqueous solution containing a high-molecular-weight molecule, the concentration device including a cylinder that accommodates a particulate super absorbent polymer and a piston that is insertable into the cylinder, where the cylinder has, at a bottom part, a liquid holding part for holding a part of the sample solution injected into the cylinder, the super absorbent polymer is accommodated in the cylinder to be in contact with the liquid holding part on the liquid holding part, and the piston includes the tip part having holes smaller than the particle diameter of the super absorbent polymer after water absorption.
CONCENTRATION DEVICE, SAMPLE SOLUTION CONCENTRATION METHOD, SAMPLE SOLUTION EXAMINATION METHOD, AND EXAMINATION KIT
There are provided a concentration device for concentrating a sample solution, which makes it possible to obtain a sample solution concentrated solution having a desired concentration fold ratio, a sample solution concentration method using the concentration device, a sample solution concentration method using the sample solution examination method, and an examination kit including the concentration device. The concentration device is a concentration device for concentrating a sample solution which is an aqueous solution containing a high-molecular-weight molecule, the concentration device including a cylinder that accommodates a particulate super absorbent polymer and a piston that is insertable into the cylinder, where the cylinder has, at a bottom part, a liquid holding part for holding a part of the sample solution injected into the cylinder, the super absorbent polymer is accommodated in the cylinder to be in contact with the liquid holding part on the liquid holding part, and the piston includes the tip part having holes smaller than the particle diameter of the super absorbent polymer after water absorption.
Methods for Modulating Bile Acid Homeostasis and Treatment of Bile Acid Disorders and Diseases
The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
Methods for Modulating Bile Acid Homeostasis and Treatment of Bile Acid Disorders and Diseases
The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
CHD risk stratification evaluations for subjects with high levels of large HDL-P
Embodiments of the invention are directed to methods, systems and computer programs that provide improved risk stratification for people having elevated large HDL-P using at least one defined HDL risk interaction parameter.
CHD risk stratification evaluations for subjects with high levels of large HDL-P
Embodiments of the invention are directed to methods, systems and computer programs that provide improved risk stratification for people having elevated large HDL-P using at least one defined HDL risk interaction parameter.
Surface modified electrodes, and methods of preparation thereof
A surface modified electrode is provided. The surface modified electrode includes a glassy carbon electrode (GCE) and a nanomaterial disposed on the glassy carbon electrode. The nanomaterial comprises carbon nanotubes (CNTs), and at least one of thallium oxide nanoparticles (Tl.sub.2O.sub.3.NPs), thallium oxide (Tl.sub.2O.sub.3) nanopowder, and thallium oxide carbon nanotube nanocomposites (Tl.sub.2O.sub.3.CNT NCs). A polymer matrix is configured to bind the glassy carbon electrode with the nanomaterial. A method of preparing the surface modified electrode is also disclosed. The surface modified electrode can be implemented in a biosensor for detecting a biological molecule, like choline.
SURFACE MODIFIED ELECTRODES, AND METHODS OF PREPARATION THEREOF
A surface modified electrode is provided. The surface modified electrode includes a glassy carbon electrode (GCE) and a nanomaterial disposed on the glassy carbon electrode. The nanomaterial comprises carbon nanotubes (CNTs), and at least one of thallium oxide nanoparticles (Tl.sub.2O.sub.3.Math.NPs), thallium oxide (Tl.sub.2O.sub.3) nanopowder, and thallium oxide carbon nanotube nanocomposites (Tl.sub.2O.sub.3.Math.CNT NCs). A polymer matrix is configured to bind the glassy carbon electrode with the nanomaterial. A method of preparing the surface modified electrode is also disclosed. The surface modified electrode can be implemented in a biosensor for detecting a biological molecule, like choline.
Lipidomics-based identification of patients bearing ovarian tumors
Methods are disclosed for treating ovarian tumors and ovarian and pancreatic cancers using computed and normalized relative ratios of plasma levels of phospholipids, particularly lysophosphatidylcholine, lysophosphatidylethanolamine, phosphatidylcholine, phosphatidylethanolamine and sphingomyelin.
Lipidomics-based identification of patients bearing ovarian tumors
Methods are disclosed for treating ovarian tumors and ovarian and pancreatic cancers using computed and normalized relative ratios of plasma levels of phospholipids, particularly lysophosphatidylcholine, lysophosphatidylethanolamine, phosphatidylcholine, phosphatidylethanolamine and sphingomyelin.